Research programme: Chimeric antigen receptor engineered cell therapies - Obsidian Therapeutics

Drug Profile

Research programme: Chimeric antigen receptor engineered cell therapies - Obsidian Therapeutics

Alternative Names: CAR cell therapies - Obsidian Therapeutics; Cell and gene therapies - Obsidian Therapeutics

Latest Information Update: 12 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Obsidian Therapeutics
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies
  • Mechanism of Action Cell replacements; Gene transference; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 12 Dec 2017 Early research in Cancer in USA (unspecified route)
  • 06 Dec 2017 Obsidian Therapeutics and Stanford University School of Medicine collaborate for developing destabilising domains to regulate CAR activity in CAR-T products
  • 06 Dec 2017 Obsidian Therapeutics in-licenses technology relating to destabilising domains from Stanford University
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top